ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

William Blair raised their Q3 2026 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the ...

Bristol-Myers Squibb (BMY) is ranked 5th among the best pharma stocks to buy according to hedge funds. The company boasts a ...

This was the stock's second consecutive day of losses.

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

WASHINGTON — The craic wasn’t all good at the White House Wednesday, as President Trump hosted Irish Prime Minister Micheál ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...

Bristol Myers Squibb’s dividend yield crossed the 4% mark, making it an attractive option for income-focused investors. The ...